Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous
thromboembolism events (VTE). This study performed a systematic review in …

A prothrombotic state is reported with severe COVID-19 infection, which can manifest in
venous and arterial thrombotic events. Coagulopathy is reflective of more severe disease …

Background Pulmonary embolisms are frequently and prognostically in individuals infected
by coronavirus disease 2019 (COVID-19); the incidence of pulmonary embolisms is varied …

Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …

Data regarding the occurrence of venous thromboembolic events (VTE), including acute
pulmonary embolism (PE) and deep vein thrombosis (DVT) in recovered COVID-19 patients …

Background Although a high prevalence of pulmonary embolism (PE) has been reported in
association with coronavirus disease 2019 (COVID-19) in critically ill patients, nationwide …

Introduction Statistical signal detection is a crucial tool for rapidly identifying potential risks
associated with pharmaceutical products. The unprecedented environment created by the …

Introduction Pulmonary embolism (PE) has not been accounted for as a cause of death
contributing to cause‐specific mortality in global reports. Methods We analyzed global PE …

Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality
among patients. Although international guidelines agree on the need for anticoagulation, it …

SARS-CoV-2 infection determines a disease that predominantly affects lungs. However the
cytokines storms, determined by the huge immune response to the infection, could affect …